Seidman A D, Scher H I, Petrylak D, Dershaw D D, Curley T
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
J Urol. 1992 Mar;147(3 Pt 2):931-4. doi: 10.1016/s0022-5347(17)37426-8.
The combination of estramustine phosphate and vinblastine sulfate, 2 agents with separate and unique antimicrotubular effects, has demonstrated additive cytotoxicity against the DU145 human prostate derived cell line in vitro. We evaluated this combination in 25 patients with progressive hormone refractory prostate cancer. Of 24 patients with an elevated prostate specific antigen (PSA) level at the start of treatment 13 (54%, 95% confidence limits 34 to 74%) had a greater than 50% decrease in PSA levels on at least 3 consecutive biweekly determinations. The median decrease in PSA in responding patients was 64% (mean 71.7%) and the median duration of response was 7 months. In 5 patients with bidimensionally measurable disease 2 partial responses were observed. Treatment was well tolerated, with mild and manageable toxicity. This is a well tolerated outpatient treatment regimen for patients with hormone-refractory prostatic cancer which deserves further investigation.
磷酸雌莫司汀和硫酸长春碱这两种具有不同且独特抗微管作用的药物，在体外已证明对DU145人前列腺来源细胞系具有相加的细胞毒性。我们对25例激素难治性前列腺癌进展患者评估了这种联合用药。在治疗开始时前列腺特异性抗原（PSA）水平升高的24例患者中，13例（54%，95%可信区间34%至74%）在至少连续3次每两周测定时PSA水平下降超过50%。有反应患者的PSA中位数下降为64%（平均71.7%），反应的中位数持续时间为7个月。在5例有二维可测量疾病的患者中观察到2例部分缓解。治疗耐受性良好，毒性轻微且可控制。这是一种耐受性良好的门诊治疗方案，适用于激素难治性前列腺癌患者，值得进一步研究。
